Skip to main content

Drug Interactions between digitoxin and Rapiblyk

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

digitoxin landiolol

Applies to: digitoxin and Rapiblyk (landiolol)

Consumer information for this interaction is not currently available.

MONITOR CLOSELY: Coadministration of landiolol with positive inotropes, vasoconstrictors, or sympathomimetic agents may decrease the therapeutic effects of landiolol. According to the package labeling, concomitant use reduced landiolol's heart rate and blood pressure lowering effects. In addition, concomitant dobutamine also reduced landiolol's effect on PR-interval prolongation.

MANAGEMENT: If coadministration is clinically necessary, careful titration of the landiolol infusion and close hemodynamic monitoring is advised. Consultation with package labeling and relevant institutional protocols may be advisable for further guidance.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer